Curemark
Rye
About Curemark
Curemark is a biopharmaceutical company that focuses on the development of novel therapies to treat serious diseases for which there are limited treatment options for patients in need. Their pipeline includes two Phase III clinical-stage programs for Autism and ADHD as well as three preclinical programs directed at Parkinson’s Disease, Schizophrenia, and Addiction. All of their product candidates address severe neurologic diseases that are currently believed to be underserved by available approved therapies and represent large potential commercial market opportunities. They believe that their product candidates offer innovative therapeutic approaches and may have the potential to provide significant advantages relative to current therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $74.4M
- Last round: Series Unknown (Apr 2021)
- Website: curemark.com
- Phone: +1 914 824 9700
Industries & Categories
Biopharma, Biotechnology, Health Diagnostics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/curemark-44932 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.